Recent events
Recent events tied to this brand in public sources.
Back to profile6 entries
2026
Pennsylvania sues insulin makers and PBMs over alleged insulin price collusion
Pennsylvania sued Eli Lilly and Co., Novo Nordisk Inc., Sanofi-Aventis US LLC, and several PBMs, alleging that they colluded to raise insulin prices. The lawsuit seeks structural changes, restitution, and financial penalties.
2026
Florida sues Prime Therapeutics and Express Scripts over alleged drug price fixing
Florida Attorney General James Uthmeier filed a lawsuit alleging that Prime Therapeutics and Express Scripts entered into an illegal agreement to fix prices on otherwise affordable drugs, citing a December 2019 collaboration in which Prime adopted Express Scripts' lower reimbursement rates.
2020
Lackie Drug Store sues pharmacy benefit managers over alleged anticompetitive practices
Lackie Drug Store Inc. filed a case in Lonoke County Circuit Court alleging that pharmacy benefit managers, including CVS Health Corporation and Caremark entities, used reimbursement methodologies and practices that were anticompetitive. The allegations include withholding Maximum Allowable Cost information and conspiracy regarding pricing rates; the source reports allegations, not a determination.
2020
Cigna and Express Scripts sue former employee
Cigna Corporation and its subsidiary Express Scripts filed suit against a former employee, accusing him of theft of trade secrets and violation of confidentiality agreements. The claims are allegations in the complaint.
2019
Harris County files insulin price-fixing lawsuit
Harris County sued insulin manufacturers Eli Lilly, Novo Nordisk and Sanofi, along with pharmaceutical benefit managers Aetna Rx, CVS Caremark, Express Scripts and OptumRx, alleging they colluded to drive up insulin prices. The county seeks to recover more than $27 million it says it has paid to the companies.
2019
Jury verdict favors Express Scripts in Micro Focus licensing dispute
A federal jury rejected Micro Focus’s arguments in its software-license dispute with Express Scripts, and the article says the jury construed the ambiguous terms against Micro Focus and found Express Scripts’ interpretation most reasonable.